The maternal immune system during pregnancy and its influence on fetal development

Sara S Morelli1
Mili Mandal2
Laura T Goldsmith1
Banafsheh N Kashani1
Nicholas M Ponzio3,4

1Department of Obstetrics, Gynecology and Women’s Health, New Jersey Medical School, Rutgers University, Newark, New Jersey
2Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey
3Department of Pathology and Laboratory Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey
4Graduate School of Biomedical Sciences, Rutgers University, Newark, New Jersey, USA

Correspondence: Sara S Morelli
Department of Obstetrics, Gynecology and Women’s Health, New Jersey Medical School, Rutgers University, MSB E-506, 185 South Orange Avenue, Newark, NJ 07103, USA
Tel +1 973 972 4127
Fax +1 973 972 4574
Email morellsa@njms.rutgers.edu

Abstract: The maternal immune system plays a critical role in the establishment, maintenance, and completion of a healthy pregnancy. However, the specific mechanisms utilized to achieve these goals are not well understood. Various cells and molecules of the immune system are key players in the development and function of the placenta and the fetus. Effector cells of the immune system act to promote and yet limit placental development. The T helper 1 (Th1)/T helper 2 (Th2) immune shift during pregnancy is well established. A fine balance between proinflammatory and anti-inflammatory influences is required. We herein review the evidence regarding maternal tolerance of fetal tissues and the underlying cell-mediated immune and humoral (hormones and cytokines) mechanisms. We also note the many unanswered questions in our understanding of these mechanisms. In addition, we summarize the clinical manifestations of an altered maternal immune system during pregnancy related to susceptibility to common viral, bacterial, and parasitic infections, as well as to autoimmune diseases.

Keywords: maternal–fetal interface, immune system, fetal tolerance, lymphocyte subsets, decidua, pregnancy

Introduction

The relationship between mother and fetus has fascinated immunologists for decades. Survival of the semiallogeneic fetus was used by Billingham et al1 in 1953 as an example of immune tolerance to the fetus by the maternal immune system. Numerous hypotheses related to placental protection of the fetus, including expression (or lack of expression) of histocompatibility antigens on fetal tissues, maternal immune tolerance to fetal antigens, and inhibition and/or regulation of maternal antifetal immune responses have been put forth to explain the survival of the “immunogenic” fetus. Yet, the mechanisms still remain to be totally clarified.

Part of the difficulty in studying these mechanisms is due to the variation among species in which such investigations are conducted. Mice are used for many of these investigations because of their short gestational time, relatively lower cost, well-defined genetics (including mutant, transgenic, and knockout strains), and availability of a wide spectrum of antibodies and reagents to perform immunologic and molecular studies. However, differences in the reproductive system in general, and the fetomo–placental unit in particular, as well as differences in the development and function of immune elements, often preclude direct extension of results observed in mice to humans. In contrast, studies designed to investigate such questions in humans are unethical, and studies incorporating nonhuman primates for these investigations raise similar moral issues and are also prohibitively expensive.
Therefore, our review is not designed to address all the unanswered questions surrounding the significance of the maternal immune system during pregnancy and its influence on fetal development. Rather, our goals are to identify the gaps in the knowledge and understanding about the topic from the published literature about various species and to acknowledge contexts wherein differences preclude a direct comparison with humans. Notwithstanding these differences however, investigations conducted in other species, such as rodents, do serve to identify possible strategies to address some of these unanswered questions.

Additionally, we take an interdisciplinary approach as coauthors who bring clinical and basic science perspectives and expertise in reproductive and immunological disciplines. Thus, we address topics related to definition of the maternal-fetal interface, as well as the significance of maternal immune responses in regulating key early events during both pregnancy (eg, implantation, angiogenesis, and vascular remodeling) and in development of the fetal immune system. We then review current understanding about maternal tolerance of fetal tissues and the underlying cellular and humoral immune mechanisms. Finally, we examine clinical manifestations of an altered maternal immune system during pregnancy related to susceptibility to certain viral, bacterial, and parasitic infections, as well as to autoimmune disorders.

**Description and definition of the maternal-fetal interface**

**Maternal: decidua**

In women, invasion by the trophoblast is extensive, encompassing the endometrium as well as the inner third of the myometrium. To accommodate this, a pronounced remodeling process must occur, involving multiple cellular compartments of the uterus in preparation for implantation and establishment and support of pregnancy. This process, decidualization, occurs in humans on a cyclic basis beginning in the midluteal phase of the menstrual cycle, independently of pregnancy. In contrast, in rodents and most other species, decidualization requires the presence of a blastocyst. The term maternal decidua thus refers to the uterine mucosal layer (endometrium) after it has undergone decidualization, the requisite and complex differentiation process involving the multiple cellular compartments of the endometrium in preparation for embryo implantation.

The parenchymal cellular compartments of the maternal decidua include the glandular epithelial compartment, the luminal epithelial compartment, the endothelium of the spiral arteries, and the decidualized stromal cells, all of which undergo dramatic transformation in preparation for pregnancy. The glandular epithelium acquires increased secretory activity under the influence of maternal progesterone. Dramatic remodeling of spiral arteries occurs during decidualization, discussed in greater detail later in this review. The endometrial stromal fibroblasts that undergo dramatic morphologic and biochemical differentiation in preparation for implantation and support of pregnancy become known as decidual cells, or decidualized stromal cells. Decidualized stromal cells no longer have the characteristic spindle shape of the endometrial stromal fibroblast and, instead, have acquired an epithelioid phenotype, characterized by progressive cell enlargement, rounding of the nucleus, and expansion of the rough endoplasmic reticulum and Golgi complex, all consistent with the transformation into a secretory cell. Major secretory products of decidualized stromal cells include prolactin and insulin-like growth-factor-binding protein-1, the hallmark proteins widely used as phenotypic markers of decidualization. These cells also secrete a number of cytokines and growth factors (eg, interleukin [IL]-11, epidermal growth factor [EGF], heparin-binding EGF-like growth factor), which further regulate the process of decidualization in an autocrine and/or paracrine manner.

In addition to the parenchymal cellular compartments making up the maternal decidua, various populations of immune cells exist in the human endometrium throughout the menstrual cycle. In early pregnancy, leukocytes are abundant, comprising 30%-40% of all human decidual stromal compartment cells. The basalis layer of the human endometrium contains lymphoid aggregates composed of T-cells and a small number of B-cells. In the functionalis layer of the proliferative phase, few uterine natural killer (uNK) cells, T-cells, and macrophages are scattered throughout the stromal compartment. Although the numbers of T-cells and macrophages remain largely unchanged throughout the luteal phase and during the process of decidualization, there is a dramatic increase in the number of uNK cells postovulation, playing a critical role in preparation of the endometrium for pregnancy. With regard to decidual immune cell populations during early pregnancy, studies using flow cytometry and immunostaining of human tissues demonstrate that the majority of first-trimester human decidual leukocytes are uNK cells (~70%), followed by macrophages (~20%). T-cells make up approximately 10%-20% of decidual leukocytes, and dendritic cells (DCs) and B-cells are rare. As in humans, uNK cells are the predominant leukocyte population in the decidua of the rhesus macaque and the mouse, but studies to determine relative numbers of other leukocyte populations in
murine decidua are lacking. The functions of each immune cell type at the maternal–fetal interface are discussed in more detail in this review, with a particular focus on uNK cells.

**Fetal: placenta, fetal membranes (amnion and chorion)**

Structurally, the interface between the uterine mucosa and the extraembryonic tissues is commonly referred to as the maternal–fetal interface. This is represented in Figure 1, which depicts the maternal immune cells and the fetal trophoblast.

Extraembryonic cells in direct contact with maternal cells are the trophoblast cells, derived from the trophectoderm layer surrounding the blastocyst. In women, invasion by the trophoblast into maternal spiral arteries substantially increases uterine blood flow, puts maternal blood in direct contact with fetal trophoblast cells, and ensures sufficient delivery of maternal nutrients and oxygen to the placenta. However, the maternal and fetal circulations do not mix. After attachment of the blastocyst to the endometrial luminal epithelium, trophoblast cells invade the decidua as depicted in Figure 1. The trophoblast, composed of an inner cell layer (cytotrophoblast) and outer cell layer (syncytiotrophoblast), does not give rise to the fetus itself, but rather to the placenta and fetal membranes (amnion and chorion). As the blastocyst and surrounding trophoblast invade the decidua, one pole of the blastocyst remains oriented toward the endometrial lumen, and the other remains buried in the decidua, which will develop into the anchoring cytotrophoblasts and villous trophoblasts, contributing to formation of the placenta, chorion, and amnion. Of note are the species differences in the degree of invasion by trophoblast cells, which have been documented in detail elsewhere. In distinct contrast to the process in women, trophoblast invasion is minimal in rodents.

**Figure 1** Schematic depiction of the human maternal–fetal interface including maternal immune cells such as uterine natural killer (uNK) cells, macrophages, (the predominant immune cell types) and T helper (Th) cells, T-cytotoxic (Tc) cells, dendritic cells, as well as invading trophoblast cells.

and accounting for ∼70% of decidual leukocytes in the first trimester. It is critical to note that uNK cells are both phenotypically and functionally distinct from peripheral NK cells. Phenotypically, they are identified by expression of the NK cell marker CD56, expressed at high concentrations (CD56bright), but they lack expression of CD16, found on most peripheral NK cells (CD56dimCD16+). In terms of function, peripheral CD56dimCD16− NK cells are highly cytotoxic, mediating both natural and antibody-dependent killing, whereas uNK cells are only weakly cytotoxic and do not normally kill trophoblast cells. In addition, uNK cells are a potent source of immunoregulatory cytokines, matrix metalloproteinases (MMPs), and angiogenic factors. These various factors mediate extracellular matrix remodeling, trophoblast invasion, and angiogenesis, which are key processes in placentation and establishment of early pregnancy at the maternal-fetal interface.

In addition to uNK cells, decidual macrophages are relatively abundant, comprising ∼20% of the human deciduocyte population in the first trimester. In normal pregnancy, most of the macrophages at the maternal–fetal interface are of the M2 (immunomodulatory) phenotype. Present in decidua prior to the presence of extravillous trophoblast, macrophages play a role in early spiral artery remodeling by producing factors associated with tissue remodeling (MMP-9) and angiogenesis (vascular endothelial growth factor [VEGF]). Apoptosis is an important event during spiral artery remodeling and trophoblast invasion, and decidual macrophages phagocytose apoptotic cells in remodeled vascular wall and apoptotic trophoblast cells, thereby preventing the release of proinflammatory substances from the apoptotic cells into the decidua. First-trimester decidual macrophages may also be responsible for inhibition of human uNK cell-mediated lysis of invasive cytotrophoblast, mediated by decidual secretion of transforming growth factor-beta-1 (TGF-β1), as demonstrated in human in vitro studies. In distinct contrast to human uNK cells, which peak in number at 20 weeks gestation and are nearly absent in the decidua at term, decidual macrophages are present throughout pregnancy, but the precise role of decidual macrophages at the end of pregnancy remains unknown.

T-cells are also fairly abundant in human decidua, comprising 10%–20% of the human deciduocyte population, of which 30%–45% are CD4+ T-cells and 45%–75% are CD8+ T-cells. The main function of T-cells in the decidua, particularly of CD4+ T-regulatory (Treg) cells, is generally thought to be the promotion of tolerance to the fetus (discussed in detail later in this review). However, because a variety of different T-cell subsets are present, the complex interactions of T-cells in the decidua have not been completely defined. Human in vitro studies of CD8+ T-cells isolated from first-trimester decidua demonstrate that these cells exhibit cytotoxic activity as well as cytokine production (predominantly interferon-gamma [IFN-γ] and IL-8). Since decidual CD8+ T-cell supernatants increase the in vitro invasive capacity of extravillous trophoblast cells, secreted products of CD8+ T-cells may play a role in regulation of trophoblast invasion, but precise mediators have not yet been identified.

DCs, which are antigen-presenting cells that play a critical role in regulation of the adaptive immune response, make up a very small portion of human decidual leukocytes. However, no single specific marker for DCs exists and their phenotypic definition is therefore controversial, thereby limiting the existing studies of decidual DCs. Using lineage-negative and human leukocyte antigen-DR-positive (HLA-DR+) status as a combination marker for DCs, Gardner and Moffett demonstrated that decidual DCs comprised 1% of first-trimester human decidual leukocytes. Due to the rarity of this cell population, functional studies of human decidual DCs are scarce. Human in vitro studies have demonstrated that decidual DCs, isolated from early-pregnancy decidua, are more likely than peripheral DCs to prime naïve CD4+ T-cells into a Th2 phenotype, suggesting a potential role for decidual DCs in averting Th1-mediated rejection of the fetus. Decidual DCs also appear to regulate uNK cell function, since coculture of decidual DCs with uNK cells stimulated uNK cell proliferation and activation. In vivo functional studies of decidual DCs exist only in mice and are more definitive. Decidual DC–depleted mice exhibit severely impaired implantation, impaired decidual proliferation and differentiation, impaired angiogenesis, impaired differentiation of uNK cells, and resorption of embryos. Therefore, at least in mice, decidual DCs play an important role in deciduization and establishment and maintenance of early pregnancy.

**Mechanisms by which immune cells (focus: uNK cells) regulate key early events in establishment of pregnancy: implantation, angiogenesis, and vascular remodeling**

Studies performed by Hanna et al provided strong evidence that human uNK cells play a role in regulation of
The endothelium of these vessels is replaced by extravillous decidual spiral arteries must be transformed into larger-as well as to support the demands of a growing fetus. The role of uNK cells in angiogenesis and vascular remodeling in early pregnancy is regulated, at least in part, by the various cytokines derived from human decidual NK cells. The ability of uNK cells present in decidua to inhibit trophoblast invasion, as demonstrated by Lash et al, using in vitro Matrigel invasion assays. These investigators demonstrated that human uNK cells isolated from first-trimester human decidua are a source of IFN-γ, which inhibits trophoblast invasion by increasing apoptosis of extravillous trophoblast cells and decreasing trophoblast secretion of MMP-2. Thus, the fine balance required to avoid either underinvasion or overinvasion of trophoblast in early human pregnancy is regulated, at least in part, by the various cytokines derived from human uNK cells present in decidua.

Role of uNK cells in angiogenesis and vascular remodeling in early pregnancy

In humans, extensive vascular remodeling must occur to allow for placentation and establishment of early pregnancy, as well as to support the demands of a growing fetus. The decidual spiral arteries must be transformed into larger-diameter vessels with low resistance and high flow, capable of transporting nutrients and oxygen to the fetus. In addition, the endothelium of these vessels is replaced by extravillous trophoblast cells that have migrated from the placenta, allowing for diversion of blood flow into the space surrounding the placental villous tree and thereby permitting nutrient and gas exchange between mother and fetus. Not only is adequate vascular remodeling critical for the establishment of a normal pregnancy, but abnormalities in these early events are associated with later complications of pregnancy such as preeclampsia and intrauterine growth restriction, which can have a major impact on fetal and neonatal health.

A critical role for uNK cells in vascular remodeling has been demonstrated in both murine in vivo and human in vitro studies. However, it is important to note significant differences among species in terms of strategies to increase blood flow to the site of maternal–placental exchange. In humans, extensive invasion and destruction of preexisting arteries by trophoblast occurs. In nonhuman primates such as rhesus macaques, trophoblastic invasion and modification of uterine arteries occurs, but unlike in humans, invasion of decidual stroma by trophoblast in the rhesus monkey occurs only to a minimal extent. In mice, the extent to which the trophoblast invades both the decidual stroma and uterine arteries is even more limited. Rodent models thus have limited value in advancing our understanding of mechanisms of vascular remodeling that facilitate human pregnancy. Nevertheless, there are in vivo studies performed in mice that cannot be performed in humans, and the availability of nonhuman primates for such in vivo studies in early pregnancy is limited. Therefore, much of the existing data on uNK cell functions in vascular remodeling are derived from murine studies.

Multiple murine in vivo studies demonstrate that uNK cells play a critical role in the remodeling of endometrial spiral arteries both prior to and during pregnancy. The earliest studies demonstrating a critical role for uNK cells in vascular remodeling in pregnancy were those conducted by Guimond et al., who demonstrated several reproductive abnormalities in the TgE26 mouse strain, which is deficient in NK cells. Multiple vascular abnormalities associated with implantation sites, including thickening of the media and adventitia, endothelial damage, reduction in placental size, and onset of fetal loss at Day 10 of gestation, were demonstrated in NK-cell-deficient mice. Subsequent studies from the same laboratory demonstrated that bone marrow transplantation from severe combined immunodeficient mice (which lack T- and B- lymphocytes but not NK cells) to NK-cell-deficient mice led to restoration of the uNK cell population in recipients, reduced anomalies in decidual blood vessels, increased placental size, and restored fetal
viability. Overall, these studies provide strong support for a critical role of murine uNK cells in decidualization, placentation, and the appropriate vascularization of implantation sites.

The role of murine uNK cells in vascular remodeling and decidualization appears to be mediated via IFN-γ, since transgenic mice that lack IFN-γ or its receptor fail to initiate modification of decidual arteries and exhibit necrosis of decidual cells, and treatment of NK-deficient mice with recombinant IFN-γ rescues decidual morphology and initiates decidual vessel development. However, whether human uNK cells regulate decidual vascular remodeling via IFN-γ is yet to be definitively determined. The data regarding IFN-γ expression by human uNK cells are conflicting, likely due to differences in methodology between studies and the status of cytokine stimulation of the uNK cells being studied. Evidence for production of IFN-γ in unstimulated human uNK cells is limited, but after exposure to stimulatory cytokines such as IL-2, IL-12, or IL-15, human uNK cells isolated from first-trimester decidua exhibit significantly increased IFN-γ secretion. In addition, because IFN-γ is rapidly secreted once produced, and expression of IFN-γ mRNA and protein by human uNK cells rapidly decreases after 24–48 hours in culture, conflicting data regarding IFN-γ expression by human uNK cells may be attributable to length of time in culture before measurement. In a nonhuman primate model of early pregnancy, the major population of CD56bright uNK cells isolated from early-pregnancy rhesus monkey decidua is not a source of IFN-γ. Therefore, while compelling evidence exists to support the role of IFN-γ in decidual vascular remodeling in rodents, whether uNK cell-derived IFN-γ plays an equally important role in vascular remodeling in humans and in nonhuman primates remains unclear.

Rather, the finding that human uNK cells isolated from first-trimester decidua are a potent source of the angiogenic factors angiopoietin (Ang)1, Ang2, VEGF, and PLGF supports an important role for these cells in the vascular remodeling required for successful human pregnancy. Functional studies by Hanna et al have demonstrated that human uNK cells isolated from first-trimester decidua are potent secretors of angiogenic factors such as VEGF and placental growth factor (PLGF). Supernatants derived from human uterine (but not peripheral) NK cells promoted in vitro angiogenesis, as demonstrated by an increased ability of human umbilical vascular endothelial cells to form network-like structures, a process inhibited in the presence of VEGF- and PLGF-neutralizing proteins. In addition, these investigators demonstrated the in vivo ability of human uNK cells to promote angiogenesis and growth of human trophoblast choriocarcinoma (JEG-3) tumor cells when injected subcutaneously into nude mice. In vivo angiogenic properties of uNK cells were inhibited in the presence of a VEGF- and PLGF-neutralizing protein. These studies provide strong evidence that the angiogenic properties of human uNK cells are mediated, at least in part, by their secretion of VEGF and PLGF.

### Influence of maternal immune response on development of the fetal immune system

Compelling clinical data demonstrate that children of mothers exposed to certain infectious organisms during pregnancy have significantly higher frequencies of neurological disorders, including schizophrenia and autism spectrum disorders. Rodent studies in which the maternal immune system is activated during pregnancy replicate these clinical findings and provide validated mouse models of these disorders. Thus, maternal immune stimulation during pregnancy acts as an environmental risk factor that affects development of the brain and the immune system in the offspring.

The underlying mechanisms of these phenomena have been studied primarily in prenatal rodent models, in which pregnant dams are injected with either infectious pathogens or synthetic agents that mimic viral or bacterial infections (namely, lipopolysaccharides and polyinosinic:polycytidylic acid (poly(I:C))). Offspring of such immunostimulated pregnant dams exhibit immune dysregulation and behavioral abnormalities, as well as chemical and structural anomalies of the brain, which are similar to those seen in individuals with schizophrenia and autism spectrum disorders.

There is a transient increase of cytokines (IL-1, IL-6, IL-12, tumor necrosis factor-alpha [TNF-α], granulocyte-macrophage colony stimulating factor) in the blood and amniotic fluid of immunostimulated pregnant dams, which appears to influence development of the fetal immune system, a concept known as “fetal programming.” Mammalian studies in which the maternal immune system is activated during pregnancy have also shown that offspring of immunostimulated pregnant dams exhibit accelerated development and heightened responsiveness of Th1, Th17, and cytotoxic effector T-cell subsets, indicating a proinflammatory phenotype in these offspring.

We hypothesized that in utero exposure of the fetus to cytokines elicited by maternal immune stimulation acts as a “first hit” to influence fetal programming of the immune system.
system, which persists postnataally and into adulthood. Such alterations of normal fetal programming results in development of a “proinflammatory” phenotype, and upon subsequent postnatal exposure to an immune stimulus (ie, second hit), the offspring of the immunostimulated pregnant dams exhibit exacerbated responses in comparison to offspring of phosphate-buffered saline (PBS)-injected dams. Such a scenario is also consistent with the “multiple hit” concept of mental disorders.\(^{81,82}\) In the context of neurodevelopmental disorders, this would mean that abnormalities of behavior and immune dysregulation observed in some affected children could reflect such altered fetal programming that is manifested postnatally upon encounter with a second hit (eg, infection) to their immune system. We tested this hypothesis in adult offspring of immunostimulated pregnant dams using well-documented in vivo experimental models that involve activation of the innate and/or adaptive immune systems. In each of these models, the adult offspring of immunostimulated dams mounted a more robust inflammatory response than adult offspring of control dams injected with PBS.\(^{73,80}\) Thus, offspring from immunostimulated dams exhibit behavioral anomalies reminiscent of those seen in individuals with some neurodevelopmental disorders, such as schizophrenia and autism. In addition to their behavioral abnormalities, our studies show that as a result of in utero exposure to products of maternal immune stimulation, these adult offspring also exhibit a “proinflammatory” phenotype that confers a vulnerability to develop immune-mediated pathology after birth and into adulthood.\(^{73,74,80}\)

In this regard, the results obtained from our investigations in mouse models have provided the scientific rationale for an ongoing translational research project to determine whether similar molecular pathogenic mechanisms are involved in a cohort of autistic children who also exhibit diagnostic evidence of immune dysregulation.\(^{84}\) Using DNA obtained from the Autism Genetic Resource Exchange database, we initiated a study to determine whether polymorphisms in selected maternal cytokine genes occurred more frequently in mothers of these autistic children. Our results show that mothers of autistic children in this cohort have significantly higher frequencies of proinflammatory cytokine gene polymorphisms, thereby conferring the genetic capability to respond more vigorously to immune stimulation by producing the types and amounts of cytokines that promote inflammatory reactions. Moreover, analysis of preliminary data from the offspring indicates that the autistic children of these mothers inherit the maternal genotype. Thus, results obtained from our investigation of the experimental prenatal mouse model of maternal immune stimulation during pregnancy\(^{71}\) appear to have biological relevance to humans.

## Maternal–fetal tolerance

Billingham et al\(^1\) in 1953 were the first to propose the concept of immune tolerance during pregnancy. They hypothesized that the semiallogeneic fetus is able to survive due to regulation of the immunologic interactions between mother and fetus. Such regulation can be caused by a lack of fetal antigen expression and/or functional suppression of maternal immune response.\(^1\)

HLAs that are expressed in the fetal membranes are tolerogenic rather than immunogenic,\(^{85}\) and expression of major histocompatibility complex (MHC) proteins at the maternal–fetal interface is tightly regulated during pregnancy.\(^{86}\) The MHC class I genes are subdivided into classes Ia and Ib. The MHC class Ia is further subdivided into HLA-A, B, and C and class Ib is subdivided into HLA-E, F, and G. HLA class II (HLA-D) genes are not translated in human trophoblast cells.\(^{87}\) Human trophoblast cells express one MHC class Ia (HLA-C) and all MHC class Ib molecules. In human placenta, fetal trophoblast cells do not express MHC class Ia (HLA-A and B) molecules that are responsible for the rejection of allografts in humans.\(^{88,89}\) Interactions between HLA-C and decidual NK cells may also cause infiltration of trophoblast into maternal tissue. Pregnancies with mismatched fetal HLA-C exhibit a greater number of activated T-cells and functional Tregs in decidual tissues compared to HLA-C-matched pregnancies.\(^{90}\) This suggests that in uncomplicated pregnancies, decidual T-cells recognize fetal HLA-C at the maternal–fetal interface but are prevented from inducing a destructive immune response.\(^{91}\)

Regarding pregnancy, one of the most important questions is how the fetal–placental unit escapes maternal rejection. Although there is a continuous interaction between the fetus and maternal cells throughout pregnancy, the fetus acts as a privileged site that is protected from immune rejection.\(^{91}\) Expression of MHC molecules on trophoblast cells is repressed in most of the species as a strategy to avoid recognition and destruction by the maternal immune cells.\(^{92}\) Peripheral blood lymphocytes from pregnant mares demonstrate reduced capacity to develop into effector cytotoxic T lymphocytes.\(^{93}\) This reduction in T-cell-mediated alloreactivity returns to normal after termination of pregnancy and is not observed in nonpregnant mares. In addition, extracts from Day 80 placentas from mares have been shown to inhibit proliferation of
maternal lymphocytes, and coculture of trophoblast cells with maternal lymphocytes caused reduction in proliferation and cytokine production.  

**Cell-mediated immunity: mechanisms promoting maternal–fetal tolerance**

**The Th1–Th2 shift in pregnancy**

Pregnancy is a complex immunological state, wherein the mother must tolerate the “foreign” fetus, and thus requires a degree of immunosuppression. On the other hand, the mother must maintain sufficient immune function to fight off infection. One mechanism that plays a role in maintenance of successful pregnancy is a switch from the Th1 cytokine profile to the Th2 profile. This switch is more prominent at the maternal–fetal interface. Th2 cells accumulate in decidua, and uterine DCs can drive naïve T-cells to become Th2 cells. Therefore, the switch to a Th2 phenotype is due to both migration of Th2 cells and induction of Th2 cells at the maternal–fetal interface, but there is little change in the systemic immune system. The hypothesis of Th2 predominance and downregulation of Th1 response during pregnancy was proposed by Wegmann et al, which is supported by both murine and human studies. In mice, the proinflammatory cytokines IFN-γ and TNF-α, or stimulation of toll-like receptors, induce miscarriage, which can be reversed by inhibitors of Th1 cytokines or by administration of anti-inflammatory IL-10 (Th2 cytokine). However, IFN-γ also plays an important role in vascular remodeling in early murine pregnancy. Therefore, Th1-type immunity appears to be controlled to avoid overstimulation during pregnancy. Progesterone, estradiol, prostaglandin D2 (PGD2), and leukemic inhibitory factor generated during pregnancy promote the Th2 profile and are, in part, responsible for the Th2 bias associated with normal pregnancy. However, transgenic Th2 cytokine single-knockout mice such as IL-4−/−, IL-10−/−, 99,99 and mice with single, double, triple, and quadruple gene deletions of IL-4, IL-5, IL-9, and IL-13 have normal pregnancies, suggesting that a predominant Th2-type immunity might not be essential for successful pregnancy.

An increase of Th2 cytokines IL-4, IL-10, and monocyte-colony stimulating factor in the peripheral blood and the maternal–fetal interface is associated with successful pregnancy. Trophoblast, decidua, and amnion contribute to the Th2 cytokine-biased environment by production of IL-13, IL-10, IL-4, and IL-6. Human placental cytotrophoblasts have been shown to produce the immunosuppressive cytokine IL-10. In addition, macrophages and Tregs present within decidua during pregnancy also produce IL-10 and are involved in maintenance of immune tolerance toward allogeneic fetal antigens. The placenta also produces PGD2, which can act as a chemoattractant for Th2 cells to the maternal–fetal interface via the Th2 receptor CRTH2 (a chemoattractant receptor-homologous molecule expressed on Th2 cells). Women suffering recurrent pregnancy loss have reduced expression of CRTH2+ cells than women undergoing elective termination of pregnancy. Anti-inflammatory cytokines IL-4 and IL-10 inhibit Th1 cells and macrophages, which in turn prevent fetal allograft rejection. In addition, these cytokines also inhibit TNF-α, cyclooxygenase-2 (COX-2), and prostaglandin E2 in amnion-derived cells, which prevent the onset of labor.

Labor is often associated with a proinflammatory state with reversal back to Th1 rather than Th2. Studies indicate increases in Th1 proinflammatory cytokines and reduction in Th2 cytokines in women who are in active labor. Fetal membranes, myometrium, amnion, amniotic fluid, and decidua produce proinflammatory cytokines IL-1β and TNF-α at term and can induce nuclear factor kappa B. This transcription factor regulates the expression of labor-associated genes such as COX-2, IL-8, and MMP-9 and triggers a cascade of labor-inducing events. Despite the proinflammatory nature of Th1 cytokines, they are essential for successful pregnancy, contributing to timely labor.

**Role of Tregs in pregnancy**

CD4+CD25+ Tregs are a subpopulation of T-cells responsible for the maintenance of immunological self-tolerance by suppressing self-reactive lymphocytes in a cell contact-dependent manner by production of TGF-β and IL-10. Tregs express transcription factor forkhead box transcription factor (FoxP3), which acts as a major regulator in their development and function. There are two main Treg subsets: naturally occurring or thymic Tregs (tTregs) and induced or extrathymic/peripheral Tregs (pTregs). tTregs are CD4+CD25+Foxp3+ and express cytotoxic T lymphocyte-associated antigen 4. pTregs develop from naïve T-cells after exposure to antigens in the periphery and exposure to either IL-10 or TGF-β and can be either Foxp3- or Foxp3+. Owing to their immunosuppressive function, Tregs also play a key role during pregnancy by maintaining maternal–fetal tolerance.

Several studies have confirmed an increase in Tregs during pregnancy in blood, lymph nodes, and thymus, followed by decrease from midgestation onward until they reach nonpregnant levels at term or shortly thereafter. They play a critical role in embryo implantation and in the maintenance
of the maternal immune tolerance against semiallogeneic fetal antigens.\textsuperscript{116,117} Evidence suggests that Tregs during pregnancy are specific to paternal alloantigens, which protects the fetus from rejection by the mother’s immune system.\textsuperscript{118} Expansion of Tregs in decidua from normal pregnant women suppresses maternal Th1/Th17 activity on the semiallogeneic fetus.\textsuperscript{119}

Murine experiments have shown increased levels of Tregs in both syngeneic and allogeneic matings, suggesting alloantigen-independent Treg expansion.\textsuperscript{120} Treg expansion appears to be regulated by estradiol. This is supported by in vitro studies, which show that physiological levels of estradiol not only expand Tregs but also stimulate conversion of CD4+CD25− T-cells into CD4+CD25+ T-cells.\textsuperscript{121} On the other hand, Zhao et al\textsuperscript{122} observed no increase in Tregs in ovariectomized mice. Moreover, they detected higher number of Tregs in pregnant mice from allogeneic versus syngeneic matings, suggesting an involvement of paternal antigens in Treg expansion.\textsuperscript{122} Recently, Robertson et al\textsuperscript{123} showed that seminal fluid can drive Treg expansion. Therefore, both antigen-dependent and antigen-independent mechanisms are likely to be involved in Treg expansion.

Tregs express various chemokine receptors whose ligands are expressed at the maternal–fetal interface, which might contribute to chemokine-mediated migration of Tregs to the decidua.\textsuperscript{120} Furthermore, other immune cells produce large amounts of CCL17, CCL4, and CCL1,\textsuperscript{124–126} which might attract Tregs specifically expressing CCR4 and CCR8.\textsuperscript{127,128} Besides chemokine-mediated migration of Tregs, integrins, similar to CD62L, seem to play an important role in Treg migration, as neutralizing CD62L-specific antibody blocks expansion of Tregs in draining lymph nodes and results in allograft rejection. Schumacher et al\textsuperscript{129} have shown the importance of human chorionic gonadotropin as one of the main attractants of Tregs to the maternal–fetal interface.

Aluvihare et al\textsuperscript{117} first noted that Tregs increased in all lymphoid organs in allogeneic matings of C57BL/6 female mice with CBA males. They also adoptively transferred lymphocytes from BALB/c females, either allopregnant from C57BL/6 males or synpregnant from BALB/c males, into T-cell-deficient BALB/c females, which were then mated with C57BL/6 males. Pregnancy proceeded normally when whole lymphocyte populations were transferred. In contrast, lymphocytes depleted of Tregs resulted in fetal resorptions, and there was a massive infiltration of T-cells into the implantation sites.\textsuperscript{179} Zenclussen\textsuperscript{130} and Zenclussen et al\textsuperscript{131} have shown complete prevention of abortion in the CBA × DBA/2J model of naturally occurring spontaneous abortions by transferring Tregs from alloimmunized mice, and they also reported that no abortions occurred in the CBA × BALB/c and CBA × CBA control matings. Finally, Chen et al\textsuperscript{116} demonstrated that stimulation of Tregs, either directly by low dose of IL-2 or indirectly by Fms-related tyrosine kinase 3 ligand, led to normal pregnancy rates in CBA × DBA/2J abortion-prone mice. The results of these experiments all demonstrate that in allogenic matings, Tregs are necessary for prevention of a maternal immune response against the fetus.

Clinical manifestations of an altered immune system in pregnancy

The notion of pregnancy as an altered state of immune suppression is well documented.\textsuperscript{132–136} Pregnancy is a time period that poses a risk of increased susceptibility to infectious diseases, and the maternal immune system is solely responsible for defending against infectious microorganisms and protecting the fetus because both the fetal and the placental responses are limited.\textsuperscript{132,136} The Th1/Th2 immune shifts in pregnancy are well established and have provided a platform to further study the immune system.\textsuperscript{136} This has led to refining our understanding about the immune system and the development of a new paradigm regarding pregnancy and immune function. This newer theory proposes that the immune system during pregnancy is a functional and active system, wherein not only a maternal immune response exists but also a fetal–placental immune response, which in combination is powerful in defending both the mother and the fetus.\textsuperscript{133,136} With this notion, the immune system is not suppressed, but rather in a modulated state, and therefore, this explains why pregnant women have differential responses to various pathogens.\textsuperscript{133} During this altered response, signals are generated in the placenta, which modulate the maternal immune system to behave uniquely to different microorganisms.\textsuperscript{133} Although these old and new paradigms surrounding the immunology of pregnancy differ, it is clear that the immune system’s goal in pregnancy is to ensure that a pregnancy progresses successfully, while still providing protection for both mother and fetus from external pathogens.

Endocrine regulation of immune cells

Hormone concentrations vary with the initiation of pregnancy, and there are specific fluctuations in hormone levels throughout each trimester of pregnancy. In general, pregnancy hormones are thought to suppress maternal alloresponses, while promoting
pathways of tolerance.\textsuperscript{137} Hormonal shifts are thought to reduce the number of DCs and monocytes, decrease macrophage activity, while blocking NK cells, T-cells, and B-cells.\textsuperscript{137} Each of the major pregnancy-associated hormones is thought to directly and indirectly affect the function of the major immune cells and thus impacts the immune milieu during pregnancy. These alterations are discussed in Table 1.

### Evidence of altered immune function in pregnancy: effects of infectious organisms on pregnancy

The alterations in the immune system during pregnancy are well established, and subsequently, these changes result in increased susceptibility to certain viral, bacterial, and parasitic infections.\textsuperscript{132} This increased susceptibility is believed to result from the suppression of cell-mediated immunity, as pregnancy promotes a shift away from the Th1 to the Th2 immune environment.\textsuperscript{132,134} Additionally, infection with certain pathogens has been documented to result in severe symptoms in pregnant patients because of these immune changes.\textsuperscript{133,138} However, it is important to note that, in certain infectious diseases among gravid patients, the morbidity and mortality vary between developed and nondeveloped countries. For example, pregnant women with varicella in the US or Canada fare better than those diagnosed in underdeveloped countries, where resources are limited.\textsuperscript{139} Thus, some bias may result when evaluating the severity of disease states in pregnant women depending on geographical distribution.

Table 2 summarizes the more commonly recognized and studied pathogens related to pregnancy. As seen in Table 2, infectious diseases during pregnancy are associated with not only maternal risks but fetal risks as well. These fetal effects result from infections that cross the placenta, which can cause miscarriage, congenital anomalies, or even fetal death.\textsuperscript{133} As a result, the American Congress of Obstetricians and Gynecologists and the US Centers for Disease Control and Prevention recommend that all women be vaccinated for influenza and tetanus, diphtheria, and pertussis (Tdap) during pregnancy.\textsuperscript{140–142} Both these vaccines appear to be safe when administered during pregnancy, with few maternal and fetal adverse events.\textsuperscript{142,143} In contrast, live vaccines, such as measles–mumps–rubella (MMR) and varicella, are not

### Table 1: Endocrine regulation of immune cells and immune function

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Th1 (proinflammatory) pathway</th>
<th>Th2 (anti-inflammatory) pathway</th>
<th>Effects on immune cells</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (E2)</td>
<td>Inhibits pathway via ↓ TNF-α, IL-1β, and IL-6</td>
<td>Stimulates pathway via ↑ IL-4, IL-10, TGF-β, and IFN-γ</td>
<td>Modulates lymphocyte development and function</td>
<td>134,148</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E2 ↑ Treg proliferation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E2 enhances Treg’s suppressive function</td>
<td></td>
</tr>
<tr>
<td>Progesterone (P4)</td>
<td>Inhibits pathway via ↓ TNF-α and IL-6</td>
<td>Stimulates pathway via ↑ IL-4, IL-10 (from T-cells)</td>
<td>P4 ↑ Treg proliferation</td>
<td>134,148–151</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>P4 enhances Treg’s suppressive function</td>
<td></td>
</tr>
<tr>
<td>Human chorionic gonadotropin (hCG)</td>
<td>Inhibits pathway via ↓ TNF-α</td>
<td>Stimulates pathway via ↑ TGFβ3, IL-8, and IL-10 (from B-cells)</td>
<td>P4 suppresses T-cell activation</td>
<td>134,148,152</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wide distribution of P4 receptors in immune cells (Dendritic, T, and B-cells)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>uNK cells do not express steroid receptors, P4 actions likely mediated through glucocorticoid receptors</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>hCG attracts Tregs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>hCG induces uNK cell proliferation through mannose receptor (uNK cells do not express LH/CG receptor)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>hCG promotes dendritic cell and monocyte proliferation and function</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CD, cluster of differentiation; IL, interleukin; IFN, interferon; LH/CG, luteinizing hormone/chorionic gonadotropin; TGF, transforming growth factor; Th, T helper cell; TNF, tumor necrosis factor; Treg, T-regulatory cell; uNK, uterine natural killer; ↓, decreased; ↑, increased.
<table>
<thead>
<tr>
<th>Infectious organisms</th>
<th>Type</th>
<th>Risks</th>
<th>Transmission</th>
<th>Immune cells</th>
<th>Other</th>
<th>Fetal effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytomegalovirus (CMV)</td>
<td>Viral</td>
<td>Incidence in US: 1%-3% of pregnant women</td>
<td>Transmission: 30% in the first trimester; up to 72% in the third trimester</td>
<td>uNK cells at level of placenta</td>
<td>Most common cause of intrauterine viral infection</td>
<td>Leading cause of congenital infection (IUGR, seizures, microcephaly, petechial rash, hepatosplenomegaly), hearing and visual impairments, mental retardation, fetal death</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low risk for healthy pregnant women</td>
<td>Infection progresses from decidua → placenta</td>
<td>uNK and T-cells control CMV infection and spread during pregnancy</td>
<td>Innate response: involves pRRs that recognize viral components</td>
<td></td>
<td>36,153</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infection can spread from maternal bloodstream to decidua (preferred environment for viral infections), where the virus replicates, and then it infects fetal chorion and amnion</td>
<td>Innate response: involves pRRs that recognize viral components</td>
<td>(↑ TNF-α, ↑ G-CSF; ↓ IFN-γ, ↓ MCP-1)</td>
<td>Virus can induce apoptosis in chorion cells (direct cytopathic effect)</td>
<td>Maternal influenza infection, during any trimester, confers fourfold increased risk of bipolar disorder in offspring</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pregnant women seven times more likely to be hospitalized, twice as likely to die from influenza as nonpregnant women</td>
<td>Infection may be primary, or reactivation in utero</td>
<td>Vertical transmission occurs transplacentally</td>
<td>IAV increases gene expression of cytokines IL-1b, IL-6, TNF-α; may lead to premature rupture of membranes</td>
<td></td>
<td>145,154–156</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pregnancy decreases adiponectin levels (an adipokine) a more pronounced innate immune response when infected with H1N1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella zoster virus (VZV)</td>
<td>Viral</td>
<td>Primary varicella infection in pregnant patients leads to more severe disease than reactivation</td>
<td>Varicella pneumonia more common in pregnant women than in nonpregnant women, and presence of pneumonia confers increased risk of maternal mortality</td>
<td>Greater risk of fetal transmission when infection occurs in third trimester</td>
<td>~2.5% of varicella infections in pregnancy complicated by varicella pneumonia</td>
<td>Congenital varicella syndrome: cerebral abnormalities, cataracts, microphthalmia, chorioretinitis, mental retardation, skin lesions, limb hypoplasia, IUGR, and low birth weight</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Incidence: 0.7–3.0/1,000 pregnancies</td>
<td></td>
<td></td>
<td>Fetal effects worse if infection occurs early in pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious organisms</td>
<td>Type</td>
<td>Risks</td>
<td>Transmission</td>
<td>Immune cells</td>
<td>Other</td>
<td>Fetal effects</td>
<td>References</td>
</tr>
<tr>
<td>----------------------</td>
<td>------</td>
<td>-------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Listeriosis (L. monocytogenes)</strong></td>
<td>Bacterial</td>
<td>Infections more common during pregnancy (25%–33% of all cases occur in pregnant women)</td>
<td>Transmission: mostly foodborne</td>
<td>Innate immune response: macrophages produce IL-1, IL-6, and TNF-α; this sets stage for adaptive immune response to Listeria; CD8+ T-cells peak 7–10 days after infection</td>
<td>In pregnancy, Th17 cells, causing IL-17α and IL-22, potentiating the inflammatory response</td>
<td>Fetal effects depend on the timing of exposure to Listeria, with most infections in the third trimester</td>
<td>36,132,159–163</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pregnant women have 20-fold increased incidence of infection</td>
<td>Listeria crosses mucosal barrier in stomach, hematogenous spread to extravillous trophoblasts and chorionic villi to access placenta (decidua and placenta become major reservoirs of the organism)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tuberculosis (TB) (M. tuberculosis)</strong></td>
<td>Bacterial</td>
<td>Difficult to diagnose, due to nonspecific symptoms related to physiologic response to pregnancy (eg, fatigue, shortness of breath, sweating, cough, and mild fever)</td>
<td>Transmission via respiratory tract droplets</td>
<td>T-cells release IFN-γ in response to specific antigens presented by M. tuberculosis</td>
<td>Screening high-risk patients is imperative for early diagnosis and treatment</td>
<td>Infection can lead to miscarriage, preterm labor, stillbirth, or neonatal death (due to granulomatosis infantiseptica, causing microabscesses and granulomas)</td>
<td>164–168</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Without treatment, four times increased risk of maternal morbidity (higher rates of abortion, postpartum hemorrhage, labor difficulties, and preeclampsia)</td>
<td>Altered immunity increases susceptibility to infection and reactivation of latent TB, and risks are higher in HIV-positive women</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prevalence of active TB in pregnant patients: 0.06%–0.25% in low-prevalence countries, and 0.07%–0.5% in high-burden countries</td>
<td>Vertical transmission can occur via the placenta and amniotic fluid (congenital TB) or respiratory droplets (neonatal TB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Symptoms:** may be asymptomatic or nonspecific influenza-like, fever, back pain, and rarely gastroenteritis

**References:** 164–168

**Fetal effects:**
- Without treatment, two times increased risk of preterm birth, IUGR, low birth weight, prematurity, and six times increased risk of perinatal death
- Higher risks in patients coinfected with HIV

**Congenital TB:** neonates born to mothers with active TB have high mortality rate (20%–44%); can be subclinical or associated with birth defects
<table>
<thead>
<tr>
<th>Condition</th>
<th>Status</th>
<th>Pathogenesis</th>
<th>Maternal risks: anemia</th>
<th>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</th>
<th>Fetal risks: low birth weight and IUGR</th>
<th>Chronic infection associated with low birth weight and preterm delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Malaria</strong> (Plasmodium falciparum)</td>
<td>Parasitic</td>
<td>Pregnant women more susceptible than nonpregnant women, with higher susceptibility during first half of pregnancy</td>
<td>Placental parasites express surface ligands and antigens that differ from those of other P. falciparum variants, facilitating evasion of immune response</td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pathogenesis: infected erythrocytes accumulate in IVS (higher density than peripheral circulation) and maternal phagocytes, deposition of hemozoin (malaria pigment) seen in IVS</td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placental parasites express surface ligands and antigens that differ from those of other P. falciparum variants, facilitating evasion of immune response</td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal risks: anemia</td>
<td>Pregnancy-associated malaria causes up to 200,000 infant deaths/year</td>
<td>Fetal risks: low birth weight and IUGR</td>
<td>Chronic infection associated with low birth weight and preterm delivery</td>
<td></td>
</tr>
</tbody>
</table>
recommended during pregnancy due to the theoretical risks to the fetus.\textsuperscript{141,142}

The risk of infection during pregnancy is a serious matter, not only for concerns of maternal well-being but also the potential fetal risks, which may have long-term consequences. Animal studies have elucidated that the placentas may trigger fetal inflammatory response syndrome (FIRS), which is the diagnosis of a placental infection without the growth of an organism, from the microbiology standpoint.\textsuperscript{133,136} FIRS is serious and results in increased circulating levels of cytokines, such as IL-1, IL-6, IL-8, and TNF-\(\alpha\).\textsuperscript{133} These inflammatory shifts have been demonstrated to increase the risk of fetal abnormalities, such as ventriculomegaly or hemorrhages. Furthermore, human studies have demonstrated an association between FIRS and the development of autism, schizophrenia, neurosensorial deficits, and psychosis.\textsuperscript{133,136} These observations further validate the experimental mouse models described earlier in which immunostimulation induces high levels of proinflammatory cytokines in blood and amniotic fluid of pregnant dams, which are likely involved in the etiology of neurodevelopmental disorders exhibited in their offspring.\textsuperscript{63,72–74} In contrast, bacterial infections that reach the decidua trigger a proinflammatory response that leads to the development

<table>
<thead>
<tr>
<th>Autoimmune disease</th>
<th>Improvement (remission of symptoms)</th>
<th>Worsens (exacerbation of symptoms)</th>
<th>Other</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple sclerosis</td>
<td>Mediated via suppression of cell-mediated immunity. Reduced relapse rate mostly seen in second and third trimesters. Flares common postpartum.</td>
<td>Symptoms may worsen, improve, or remain unchanged. Symptoms vary among women and between pregnancies in the same woman.</td>
<td></td>
<td>148,173</td>
</tr>
<tr>
<td>Myasthenia gravis</td>
<td>Improvement correlated with higher levels of E2. E2 causes further shift from Th1 to Th2 type of immunity.</td>
<td>Expansion of Tregs in pregnancy may account for improvement of symptoms during pregnancy. Decrease in Tregs postpartum may account for postpartum disease flares. Fetal effects: congenital heart block, due to passive transplacental transfer of anti-Ro (SS-A) and anti-La (SS-B) Abs from mother to fetus. Causes irreversible damage to fetal cardiac conduction system. Abs also cause neonatal lupus (skin rashes, liver abnormalities, hematologic cytopenias); effects are transient (months) and improve once maternal Abs are cleared from infant’s circulation.</td>
<td></td>
<td>148,175</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>Mediated via suppression of cell-mediated immunity. Flares may occur postpartum.</td>
<td></td>
<td>Increase in Th2-mediated response worsens this humoral-mediated autoimmune disease.</td>
<td></td>
</tr>
</tbody>
</table>
| Rheumatoid arthritis | Autoimmune thyrotoxicosis may improve because of a degree of immunosuppression during pregnancy. Flare may occur postpartum. | Autoimmune disease in pregnancy due to the theoretical risks to the fetus.\textsuperscript{141,142} The risk of infection during pregnancy is a serious matter, not only for concerns of maternal well-being but also the potential fetal risks, which may have long-term consequences. Animal studies have elucidated that the placentas may trigger fetal inflammatory response syndrome (FIRS), which is the diagnosis of a placental infection without the growth of an organism, from the microbiology standpoint.\textsuperscript{133,136} FIRS is serious and results in increased circulating levels of cytokines, such as IL-1, IL-6, IL-8, and TNF-\(\alpha\).\textsuperscript{133} These inflammatory shifts have been demonstrated to increase the risk of fetal abnormalities, such as ventriculomegaly or hemorrhages. Furthermore, human studies have demonstrated an association between FIRS and the development of autism, schizophrenia, neurosensorial deficits, and psychosis.\textsuperscript{133,136} These observations further validate the experimental mouse models described earlier in which immunostimulation induces high levels of proinflammatory cytokines in blood and amniotic fluid of pregnant dams, which are likely involved in the etiology of neurodevelopmental disorders exhibited in their offspring.\textsuperscript{63,72–74} In contrast, bacterial infections that reach the decidua trigger a proinflammatory response that leads to the development
of intrauterine infections.\textsuperscript{144} This is through the activation of pattern recognition receptors (PRRs) and increased secretion of cytokines, such as IL-1 and TNF-\(\alpha\).\textsuperscript{145} Combined, these contribute to poor pregnancy outcomes, disruption in fetal development, or preterm births with resultant low-birthweight infants.\textsuperscript{146,147} Thus, it is important to recognize that pregnancy can cause increased disease susceptibility, which not only affects maternal morbidity but contributes to detrimental long-term fetal and neonatal outcomes.

Evidence of altered immune function in pregnancy: effects of pregnancy on autoimmune disease

As discussed, pregnancy confers a shift from Th1- to Th2-mediated immunity, and this shift affects disease status in women with known autoimmune diseases. In general, the hormonal milieu induced by pregnancy shifts the cytokine profile away from cell-mediated immunity (Th1 type of immunity) and, therefore, improves inflammatory-type autoimmune diseases.\textsuperscript{152} In contrast, autoimmune diseases that are humorally (or antibody) mediated are exacerbated, as pregnancy favors increased Th2-related activities, as well as a Th2 cytokine profile.\textsuperscript{132,148} For details, please view Table 3.

Conclusion and future outlook

Pregnancy in women is a dynamic state, with different mechanisms used during different trimesters to enable and ensure successful establishment, maintenance, and timely termination of the pregnancy. Mechanisms operative in early pregnancy to establish the pregnancy may differ from those needed to maintain the pregnancy and from those required to ensure successful and timely labor and delivery. Recent data challenge the notion that pregnancy is simply an immunosuppressed state protecting the allogeneic fetus from attack by the maternal immune system. The evidence suggests that rather, pregnancy may be a state of upregulated innate immune response and decreased cell-mediated response. Unique decidual lymphoid cell populations actively contribute to placentation development and to tolerance of the fetus. Although substantial progress in the understanding of the function of immune cells during pregnancy, especially early pregnancy, has been achieved, many unanswered questions regarding regulation of their proliferation and function by endocrine and other factors still remain. The published results from human studies and animal models clearly indicate that a fine balance between proinflammatory and anti-inflammatory influences is critical for successful pregnancy. Thus, the future challenge for translational research in reproductive immunology will be to define more completely those factors that favor optimal immunological environments that promote fetal health and development at specific stages of pregnancy, so that evidence-based regulatory therapeutic strategies can then be designed.

Acknowledgments

The authors thank Yingting Zhang for her assistance with the manuscript. Mili Mandal is currently affiliated with Oncology, R&D, GlaxoSmithKline, Collegeville, PA, US.

Disclosure

The authors report no conflicts of interest in this work.

References


